The journal of allergy and clinical immunology. In practice
-
J Allergy Clin Immunol Pract · Sep 2020
Multicenter StudyProspective, Single-Arm, Longitudinal Study of Biomarkers in Real-World Patients with Severe Asthma.
ARIETTA was a prospective, single-arm, noninterventional, multicenter study in patients with severe asthma. ⋯ No prognostic value for serum periostin related to exacerbations was detected. Higher blood eosinophils combined with increased FeNO were potentially associated with increased exacerbation rates.
-
J Allergy Clin Immunol Pract · Mar 2018
Randomized Controlled Trial Multicenter StudyEfficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial.
Peanut oral immunotherapy, using a variety of approaches, has been previously shown to induce desensitization in peanut-allergic subjects, but no products have been approved for clinical use by regulatory agencies. ⋯ In this study, AR101 demonstrated an acceptable safety profile and demonstrated clinical activity as a potential immunomodulatory treatment option in peanut-allergic children over the age of 4, adolescents, and young adults.
-
J Allergy Clin Immunol Pract · Nov 2017
Multicenter StudyTreatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
Clinical manifestations of hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) usually begin in childhood, often intensifying during puberty. Currently there are insufficient efficacy/safety data for HAE therapies in children and adolescents due to the small number of pediatric patients enrolled in studies. ⋯ Symptom relief was rapid, and a single icatibant injection in pediatric patients with C1-INH-HAE was well tolerated (ClinicalTrials.gov identifier, NCT01386658).
-
J Allergy Clin Immunol Pract · May 2017
Multicenter StudySevere Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study.
The severe cutaneous adverse drug reactions (SCARs) are rare but could be life-threatening. These include drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis. ⋯ SCARs in children are not common but potentially serious. Early diagnosis and appropriate treatment of SCARs will reduce the incidence of morbidity and mortality.
-
J Allergy Clin Immunol Pract · Mar 2017
Multicenter Study Comparative StudySubcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility.
Hereditary angioedema (HAE) is a life-threatening disorder characterized by recurrent angioedema. Icatibant, a subcutaneous bradykinin-B2-receptor antagonist, is an effective on-demand therapy. Data outside the United States suggest that self-administration is tolerated and patient-preferred compared with administration by health care professionals at medical facilities (HCP-administration). ⋯ Icatibant self-administration shortened attack duration and time to treatment, with no difference in safety or local tolerability compared with HCP-administration. These findings support icatibant as an effective on-demand option for home-based treatment.